Vectus Biosystems swung to a $1.56 million FY2026 profit, but the result was driven largely by the sale of its VB4-P5 compound for XORTX shares and warrants rather than recurring operations. The company is now directing its resources towards VB0004 while its auditor flags material uncertainty over ongoing funding.
- FY2026 profit of $1.56 million versus a restated $1.86 million loss
- $2.55 million net gain from the VB4-P5 transaction with XORTX
- VB0004 targeted for a Phase Ib trial in idiopathic pulmonary fibrosis
- $718,594 cash balance after $573,395 operating cash burn
- Auditor flags material uncertainty over going concern
XORTX Transaction Drives FY2026 Profit
Vectus Biosystems Limited (ASX:VBS) has reported a $1.56 million profit for FY2026, reversing a restated $1.86 million loss a year earlier. The headline turnaround was powered principally by the sale of the company’s VB4-P5 renal fibrosis compound to XORTX Therapeutics Inc., rather than by recurring operating revenue.
Vectus recorded $2.55 million in net other income from the transaction, after valuing the 154,544 XORTX shares and 692,150 pre-funded warrants received at $2.594 million and deducting $43,257 in professional and consulting costs. The securities were carried as investments worth $2.798 million at 30 June 2026, leaving the company exposed to movements in XORTX’s market value.
VB0004 Moves Towards US Regulatory Work
The company’s operational focus is now VB0004, its lead antifibrotic candidate, which Vectus plans to take into a Phase Ib clinical trial targeting idiopathic pulmonary fibrosis. After year-end, it appointed Cardinal Health Regulatory Services as its US regulatory agent to assist with an Orphan Drug Designation request, pre-IND interactions and a potential IND application.
Vectus also continued discussions with prospective pharmaceutical and biotechnology partners across VB0004, VB4-A32, VB4-A79 and its wider library of more than 1,000 small-molecule candidates. The annual report says selected potential partners have been given access to the company’s data room, but it does not disclose any completed licensing agreement or commercial terms.
Cash Improved, Funding Dependence Remains
Cash rose to $718,594 at 30 June from $250,988 a year earlier, helped by a $791,000 share placement and a $250,000 director loan. Operating cash outflow fell to $573,395 from $830,088, while operating expenses declined to $1.41 million from $2.34 million. The company also received a $421,554 research and development tax rebate during the year.
That improved balance sheet does not remove the financing question. UHY Haines Norton included a material uncertainty related to going concern in its otherwise unmodified audit opinion, pointing to the $573,395 operating cash outflow and Vectus’ dependence on future R&D rebates, capital raisings, loans, licensing activity and possible sales of XORTX securities. Total liabilities stood at $1.50 million, including $487,001 owed under director loans.
New Leadership Carries Performance Conditions
Dr Tara Speranza became CEO and chief technology officer on 7 May 2026 after consulting to Vectus since August 2025. Her package includes 109,000 shares and 981,000 zero-exercise-price options, with vesting linked to share-price milestones between 20 and 30 cents and operational targets including fundraising, clinical development and potential partnering or licensing outcomes.
The next financial test is therefore less about whether Vectus can report an accounting profit and more about whether it can convert the XORTX asset transaction and fresh funding into a sufficiently financed VB0004 programme. Regulatory engagement in the United States, progress towards the Phase Ib trial and the company’s ability to secure non-dilutive or partnership funding will determine how long the current cash position can support that plan.
Bottom Line?
The XORTX transaction strengthened Vectus’ reported equity, but VB0004 must now produce clinical and partnering progress before the company’s funding dependence becomes less pressing.
Questions in the middle?
- How quickly will Vectus advance VB0004 from regulatory preparation into its planned Phase Ib trial?
- Will the company secure a licensing or strategic partnership before additional capital is required?
- How much of the XORTX investment can be realised, and at what market value, if further liquidity is needed?